EPO Patents = 5

Forward Citations = 0

Loading Chart...

6 inventors (with patents filed for the assignee):

Michel Janicot (6 out of 6 patents)

Eugen Uhlmann (5 out of 80 patents)

Frank Jaschinski (5 out of 12 patents)

4. Eugen Leo (3 out of 3 patents)

5. Katja Wosikowski-Buters (1 out of 1 patent)

6. Petra Fettes (1 out of 1 patent)

7. Anneliese Schneider (2 patents)

8. Karl-Hermann Schlingensiepen (14 patents)

9. Reimar Schlingensiepen (0 patent)

10. Tanja Rothammer (0 patent)

6 patents: Sort by Forward Citations

1. 11207341 - TGF-beta oligonucleotide for use in treatment of ophthalmic diseases (2021-12-28),

2. 10538768 - Modified TGF-beta oligonucleotides (2020-01-21),

3. 10125368 - Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease (2018-11-13),

4. 9926563 - Modified TGF-beta oligonucleotides (2018-03-27),

5. 9840707 - Modified TGF-beta2 oligonucleotides (2017-12-12),

6. 9688988 - Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease (2017-06-27),

Isarna Therapeutics is a clinical-stage biotech company focused on developing innovative TGF-beta immunotherapies to treat cancer. The company's platform technology allows for the specific silencing of TGF-beta isoforms, disrupting the tumor microenvironment to enhance the anti-tumor immune response. Isarna Therapeutics aims to improve outcomes for cancer patients by leveraging the potential of TGF-beta modulation in oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

6 Patents

#225 in W-8000 Munich

#5,323 in Germany

Munich, Germany

Isarna Therapeutics Gmbh